P53 in Differentiated Thyroid Cancer

Cumhuriyet University

Status: Completed

Conditions: Thyroid Neoplasms

Study type: Observational

Funder types: Other

Identifiers

NCT01954134

T-485 (Other Identifier)

Details and patient eligibility

About

In clinical practise patients with negative radioiodine scan with positive tyhroglobulin is considered as radioiodine resistant or in another words in the process of dedifferentiation. The aim of the present study was to search a simple blood test that could lead to early identification of patients with dedifferentiation. In this respect, we investigate whether the serum level of anti-p53 antibody has the diagnostic value in the follow-up of patients with high levels of thyroglobulin (tg) and negative I-131 scan.

Full description

In the present study enrolled were 171 patients with mean age of 47.7±13.5 yrs (range; 16-80yrs) and 28 healthy subjects with an age range of 18-52 yrs (mean: 36.0±9.8 yrs). 134 (78.4%) patients were female and 37 (21.6%) patients were male.

Enrollment: 199 patients

Sex: All

Ages: 16 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who were diagnosed with DTC
• Treated with total and/or near-total thyroidectomy
• Referred for I-131 ablation therapy or low dose I-131 whole body scan (WBS)
• Between December 2010 and January 2013.

Exclusion criteria

• Dose 131-I given in another hospital
• Radioiodine treatment more than one year after thyroidectomy.

Trial design

199 participants in 1 patient group

thyroid cancer, healty

Description:

Thyroid cancer group: patients with differentiated or dedifferentiated thyroid cancer Healty: control group